Drugs / CT-P63
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05017168 | Oct → Nov 2021 | COVID-19 | Celltrion | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05224856 | Apr → Nov 2022 | COVID-19 | Celltrion | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-02-07 | Celltrion | Regulatory Celltrion Submits IND Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy celltrion.com ↗
Celltrion submitted an IND application for a global Phase III clinical trial of inhaled antibody cocktail therapy with CT-P59 and CT-P63; the company expects to enrol 2,200 patients with mild-to-moderate symptoms of COVID-19 |
| 2022-01-03 | Celltrion | Results Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant celltrion.com ↗
The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs). |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P63 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05224856 ↗ |
| Modality | Monoclonal antibody | “CT-P63 is a monoclonal antibody targeted against SARS-CoV-2 spike RBD as a treatment for SARS CoV 2 infection.” NCT05017168 ↗ |